Literature DB >> 8940209

Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy.

S Sei1, S K Stewart, M Farley, B U Mueller, J R Lane, M L Robb, P Brouwers, P A Pizzo.   

Abstract

The amount of human immunodeficiency virus (HIV) type 1 RNA and the presence of a codon 215 mutation indicative of zidovudine resistance were evaluated in cerebrospinal fluid (CSF) and plasma obtained from HIV-1-infected children. The level of HIV-1 RNA in CSF was highest in children with severe encephalopathy (n = 25; median, 430 copies/mL; range, 0-2.2 x 10(5) copies/mL) followed by the moderately encephalopathic (n = 7; median, 330; range, 0-1130) and nonencephalopathic groups (n = 9; median, 0; range, 0-566) (P = .007). There was no correlation between CSF and plasma HIV-1 RNA levels. Five of 7 children with the codon 215 mutation in CSF had a progression of encephalopathy, while all 8 children with wild type codon 215 had improved or stable disease during zidovudine treatment (P = .007). These findings suggest that increased viral replication and emergence of drug-resistant HIV-1 variants within the central nervous system may play a role in progression of HIV encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940209     DOI: 10.1093/infdis/174.6.1200

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus.

Authors:  Rick B Meeker; D C Bragg; Winona Poulton; Lola Hudson
Journal:  Cell Tissue Res       Date:  2012-01-27       Impact factor: 5.249

Review 2.  Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Authors:  G J Moyle; B G Gazzard; D A Cooper; J Gatell
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

3.  Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments.

Authors:  R N Shepard; J Schock; K Robertson; D C Shugars; J Dyer; P Vernazza; C Hall; M S Cohen; S A Fiscus
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.

Authors:  Sarah Benki-Nugent; Christal Eshelman; Dalton Wamalwa; Agnes Langat; Ken Tapia; Helen Moraa Okinyi; Grace John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

5.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 6.  Neurologic aspects of HIV infection in infants and children: therapeutic approaches and outcome.

Authors:  Lucy Civitello
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 7.  Involvement of quinolinic acid in AIDS dementia complex.

Authors:  Gilles J Guillemin; Stephen J Kerr; Bruce J Brew
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 8.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Early immunological predictors of neurodevelopmental outcomes in HIV-infected children.

Authors:  Jutarat Mekmullica; Pim Brouwers; Manhattan Charurat; Mary Paul; William Shearer; Hermann Mendez; Clemente Diaz; Jennifer S Read; Prosanta Mondal; Renee Smith; Kenneth McIntosh
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

10.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.